Judge maintains dismissal of US antitrust claims against Eli Lilly, Nordisk over GLP-1 drugs
( October 20, 2026, 22:31 GMT | Official Statement) -- MLex Summary: US District Judge Micaela Alvarez refused to alter a judgment that dismissed US antitrust claims against Eli Lilly and Novo Nordisk over GLP-1 drugs. “To the extent that plaintiff may be attempting to assert claims related to any production of medications that were ‘essentially copies’ of defendants’ medications while those medications were listed on the national shortage list, nowhere in plaintiff’s complaint does it allege antitrust violations related to its production of GLP-1 medications that were ‘essentially copies’ of defendants’ branded GLP-1 products during the GLP-1 national shortage, and the court declines to read any such claim into the complaint now,” Alvarez said. See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.